A practical reference on Lactam bridge: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-01. Anything still debated is marked as such rather than presented as settled.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic analogue of alpha-MSH |
| Molecular formula | C50H68N14O10 | Acetate salt form commonly reported |
| Molecular mass | ~1025 Da | Monoisotopic value near 1025.2 |
| Key structural motif | Lactam bridge | Asp side chain to Lys side chain |
| Solid appearance | White to off-white powder | Lyophilised and hygroscopic |
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Hitler's aspirations to hegemony over Europe and the establishment of the New Order, already evident from architectural and decorative features of the new Chancellery, are even more clearly expressed here. External symbols suggest that the domed hall was where Hitler as cosmocrat (Herr der Welt) would appear before his Herrenvolk: On top of the dome's lantern was the German heraldic eagle clutching the globe of the Earth (Erdball). This symbolism was well known in imperial Roman iconography, for example, the restored statue of Claudius holding a ball and eagle in his right hand. The vast dome, on which it rested, as with Hadrian's Pantheon, symbolically represented the vault of the sky spanning Germany's empire. The globe on the dome's lantern was enhanced and emphasised by two monumental sculptures by Breker, each 15 metres tall, which flanked the north façade of the building: at its west end Atlas supporting the heavens, at its east end Tellus supporting the Earth. Both mythological figures were chosen by Hitler himself. Giesler says that Speer was wrong to represent the Volkshalle as a symbol of World Domination (Weltherrschaft). Speer in his 1971 Playboy magazine interview states:
While in the healthy heart, waves of electrical impulses originate in the sinus node before spreading to the rest of the atria, the atrioventricular node, and finally the ventricles (referred to as a normal sinus rhythm), this normal rhythm can be disrupted. Abnormal heart rhythms or arrhythmias may be asymptomatic or may cause palpitations, blackouts, or breathlessness. Some types of arrhythmia such as atrial fibrillation increase the long term risk of stroke. Some arrhythmias cause the heart to beat abnormally slowly, referred to as a bradycardia or bradyarrhythmia. This may be caused by an abnormally slow sinus node or damage within the cardiac conduction system (heart block). In other arrhythmias the heart may beat abnormally rapidly, referred to as a tachycardia or tachyarrhythmia. These arrhythmias can take many forms and can originate from different structures within the heart—some arise from the atria (e.g. atrial flutter), some from the atrioventricular node (e.g. AV nodal re-entrant tachycardia) whilst others arise from the ventricles (e.g. ventricular tachycardia). Some tachyarrhythmias are caused by scarring within the heart (e.g. some forms of ventricular tachycardia), others by an irritable focus (e.g. focal atrial tachycardia), while others are caused by additional abnormal conduction tissue that has been present since birth (e.g. Wolff-Parkinson-White syndrome). The most dangerous form of heart racing is ventricular fibrillation, in which the ventricles quiver rather than contract, and which if untreated is rapidly fatal.
Titration curves can be computed within a continuum electrostatics approach with formally exact but more elaborate analytical or Monte Carlo (MC) methods, or inexact but fast approximate methods. MC methods that have been used to compute titration curves are Metropolis MC or Wang–Landau MC. Approximate methods that use a mean-field approach for computing titration curves are the Tanford–Roxby method and hybrids of this method that combine an exact statistical mechanics treatment within clusters of strongly interacting sites with a mean-field treatment of intercluster interactions.
== Fiber types == Broadly there are two types of muscle fiber: Type I, which is slow, and Type II which are fast. Type II has two divisions of type IIA (oxidative), and type IIX (glycolytic), giving three main fiber types. These fibers have relatively distinct metabolic, contractile, and motor unit properties. The table below differentiates these types of properties. These types of properties—while they are partly dependent on the properties of individual fibers—tend to be relevant and measured at the level of the motor unit, rather than at the individual fiber.
== Early life == On 20 August 2022, police announced the arrest of Brenda Cecilia Agüero (born 2 June 1995 in Buenos Aires); a nurse who worked in the neonatal unit and who had been among the suspended personnel during the initial investigation. Agüero lived with her mother and two sisters in the outskirts of Río Ceballos at the time of her arrest. Agüero graduated as a nurse with excellent results in 2018 and moved to Córdoba, where she worked at a private hospital between 2019 and December 2020, when she resigned to keep her only job at the Ramón Castillo Neonatal Hospital. Agüero denied the accusations and abstained from testifying. Days after her arrest, Agüero was formally charged with five counts of "aggravated murder for applying the insidious method of potassium incompatible with life" and eight counts of attempted murder. Agüero later accused a colleague of hers of the deaths, saying that this male nurse was present where the deaths occurred "all the time". During the legal proceedings, Agüero was incarcerated at the Bouwer prison in inner Córdoba, where she was isolated from other inmates to protect her from harm.
Sources: en.wikipedia.org
== Epidemiology == Sjögren's disease (SjD) is the third-most common rheumatic autoimmune disorder, behind rheumatoid arthritis and systemic lupus erythematosus. There are no geographical differences in the rates of Sjögren's. Sjögren's disease has been reported in all areas of the world, although regional rates have not been well studied. Depending on the criteria to determine prevalence, studies estimate the prevalence of Sjögren's at between 500,000 and 2 million people in the United States. Broader studies of Sjögren's prevalence vary widely, with some reports suggesting a prevalence of up to 3% of the population. A few studies have reported that the incidence of the syndrome ranges between three and six per 100,000 per year. Between 0.2 and 1.2% of the population is affected, with half having the primary form and half the secondary form. It is around 10 times more common in women than in men. Though the disease commonly begins in middle age, people of any age can be affected. Nine out of 10 Sjögren's patients are women. In addition to prevalence in women, having a first-degree relative with an autoimmune disease and previous pregnancies have been identified as epidemiological risk factors. Despite the lower risk for men, primary Sjögren's in men tends to represent a more severe form of the disease. The role of race and ethnicity in the prevalence of the disease is unknown. Although Sjögren's disease occurs in all age groups, the average age of onset is between 40 and 60. As many as half of all cases may be left undiagnosed or unreported.
== Fascial dynamics == Deep fascia is less extensible than superficial fascia. It is essentially avascular, but is richly innervated with sensory receptors that report the presence of pain (nociceptors); change in movement (proprioceptors); change in pressure and vibration (mechanoreceptors); change in the chemical milieu (chemoreceptors); and fluctuation in temperature (thermoreceptors). Deep fascia is able to respond to sensory input by contracting; by relaxing; or by adding, reducing, or changing its composition through the process of fascial remodeling. Fascia may be able to contract due to the activity of myofibroblasts which may play a role in wound healing. The deep fascia can also relax. By monitoring changes in muscular tension, joint position, rate of movement, pressure, and vibration, mechanoreceptors in the deep fascia are capable of initiating relaxation. Deep fascia can relax rapidly in response to sudden muscular overload or rapid movements. Golgi tendon organs operate as a feedback mechanism by causing myofascial relaxation before muscle force becomes so great that tendons might be torn. Pacinian corpuscles sense changes in pressure and vibration to monitor the rate of acceleration of movement. They will initiate a sudden relaxatory response if movement happens too fast. Deep fascia can also relax slowly as some mechanoreceptors respond to changes over longer timescales. Unlike the Golgi tendon organs, Golgi receptors report joint position independent of muscle contraction. This helps the body to know where the bones are at any given moment.
As an AAS, stanozolol is an agonist of the androgen receptor (AR), similarly to androgens like testosterone and DHT. Its affinity for the androgen receptor is about 22% of that of dihydrotestosterone. Stanozolol is not a substrate for 5α-reductase as it is already 5α-reduced, and so is not potentiated in so-called "androgenic" tissues like the skin, hair follicles, and prostate gland. This results in a greater ratio of anabolic to androgenic activity compared to testosterone. In addition, due to its 5α-reduced nature, stanozolol is non-aromatizable, and hence has no propensity for producing estrogenic effects such as gynecomastia or fluid retention. Stanozolol also does not possess any progestogenic activity of significance. Because of the presence of its 17α-methyl group, the metabolism of stanozolol is sterically hindered, resulting in it being orally active, although also hepatotoxic.
16 April The Hoa Dai refugee center in Bình Định Province was invaded by a VC armed propaganda team. The refugees were urged to return to their former (VC dominated) village, but refused; the VC burned 146 houses. After receiving a letter from Nixon affirming U.S. respect for the territory and sovereignty of Cambodia, Prince Norodom Sihanouk announced that he was ready to resume diplomatic relations with the U.S.
Sources: en.wikipedia.org
Norketamine, or N-desmethylketamine, is the major active metabolite of ketamine, which is formed mainly by CYP3A4. Similarly to ketamine, norketamine acts as a noncompetitive NMDA receptor antagonist, but is about 3–5 times less potent as an anesthetic in comparison.
This organism produces no gas or obvious taste and remains undetected by taste or smell. Its toxin is denatured by cooking, however. Cooked mushrooms, when handled poorly and then canned, can support the growth of Staphylococcus aureus, which produces a toxin that is not destroyed by canning or subsequent reheating.
Nederlands Internisten Vereniging (Dutch Internists Association) Nederlands Huisartsen Genootschap (Dutch Society of General Practitioners) Nederlands Instituut van Psychologen (Dutch Institute of Psychologists) Nederlandse Vereniging voor Kindergeneeskunde (Dutch Association for Pediatrics) Nederlandse Vereniging voor Obstetrie & Gynaecologie (Dutch Association for Obstetrics & Gynaecology) Nederlandse Vereniging voor Plastische Chirurgie (Dutch Association for Plastic Surgery) Nederlandse Vereniging voor Psychiatrie (Dutch Psychiatry Association) Transvisie (Transvision, a patient organization for transgender patients)
==== Methods of biomedical waste incineration ==== The three type of medical waste incinerators are controlled air, excess air, and rotary kiln. Controlled air is also known as starved-air incineration, two-stage incineration, or modular combustion. This is the process of which waste is fed to a combustion chamber and combustion air begins to dry and facilitates volatilization of the waste. As a result, carbon dioxide and other excess gases are released into the atmosphere. The second type of incineration is the excess air process. This is similar to the controlled air process, such as the waste being dried, ignited, and combusted by heat provided by the primary chamber burner. However, the main difference is that moisture and volatile components in the waste are vaporized. In a rotary kiln, the process is similar to the two mention above, however, it is more versatile in terms of being able to mix wet and dry waste components and viewed by many waste engineers as being the most environmentally friendly.
== Units == The dalton (symbol: Da) is the standard unit that is used for indicating mass on an atomic or molecular scale (atomic mass). The unified atomic mass unit (symbol: u) is equivalent to the dalton. One dalton is one-twelfth of the mass of one atom of carbon-12, and is 1.66053906892(52)×10−27 kg. The amu without the "unified" prefix is an obsolete unit based on oxygen, which was replaced in 1961.
Sources: en.wikipedia.org
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.
The two compounds share the same cyclic core and are both non-selective melanocortin agonists. They differ chiefly at the C-terminus, where bremelanotide carries a free carboxylic acid and melanotan II a terminal amide.
Receptor binding profiles are well characterised in vitro, but the downstream pathway linking MC4R activation to behavioural effects is not fully mapped. Several intermediate neural circuits have been proposed without definitive confirmation.
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.